Publications Diversifying the Boardroom: What Silicon Valley-Based and Other Large Public Companies Disclosed in 2022 April 10, 2023
Experience Fenwick Represents Pharmakon in Non-Dilutive Term Loan Financing for ImmunoGen April 6, 2023
Publications SBIR and STTR Applicants: Notice of Upcoming Changes Around Disclosures of Foreign Investments and Affiliations or Relationships April 6, 2023
Publications ESG Insights: Silicon Valley’s Largest Public Tech and Life Sciences Companies Stepped Up ESG Reporting Last Year April 4, 2023
Experience Fenwick Represents Blue Sky Research in Acquisition by Necsel Intellectual Property April 3, 2023
Media Coverage Fenwick Partner Robert Freedman Discusses Reverse Mergers in the Biotech Sector March 31, 2023